Your browser doesn't support javascript.
loading
SOX18 expression predicts response to platinum-based chemotherapy in ovarian cancer.
Pula, Bartosz; Kobierzycki, Christopher; Solinski, Daniel; Olbromski, Matuesz; Nowak-Markwitz, Ewa; Spaczynski, Marek; Kedzia, Witold; Zabel, Maciej; Dziegiel, Piotr.
Affiliation
  • Pula B; Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland bartosz.pula@umed.wroc.pl.
  • Kobierzycki C; Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland.
  • Solinski D; Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland.
  • Olbromski M; Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland.
  • Nowak-Markwitz E; Department of Gynecologic Oncology, University of Medical Sciences in Poznan, Poznan, Poland.
  • Spaczynski M; Department of Gynecologic Oncology, University of Medical Sciences in Poznan, Poznan, Poland.
  • Kedzia W; Department of Gynecology, University of Medical Sciences in Poznan, Poznan, Poland.
  • Zabel M; Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland Department of Histology and Embryology, University of Medical Sciences in Poznan, Poznan, Poland.
  • Dziegiel P; Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland Department of Physiotherapy, University School of Physical Education in Wroclaw, Wroclaw, Poland.
Anticancer Res ; 34(8): 4029-37, 2014 Aug.
Article in En | MEDLINE | ID: mdl-25075026
ABSTRACT

BACKGROUND:

SOX18 is a transcription factor known to be involved in blood and lymphatic vessel, hair follicle development, and wound healing processes. In addition, it has been reported that SOX18 may influence cancer growth. The role of SOX18 expression in ovarian cancer (OC) has not been determined. MATERIALS AND

METHODS:

SOX18 expression was assessed in 85 OC cases using immunohistochemical methods and in ovarian cancer cell lines on the mRNA and protein level.

RESULTS:

SOX18 was expressed in cancer cell nuclei as well as the cytoplasm. Higher nuclear SOX18 expression was associated with presence of residual disease following surgical treatment (p=0.0158) and advanced disease stage (p=0.0056). Univariate survival analysis revealed that high SOX18 (p=0.0125) expression, presence of residual disease (p<0.0001) and advanced disease stage (p<0.0324) predicted poor patient outcome.

CONCLUSION:

SOX18 may be a new predictive marker for OC.
Subject(s)
Key words
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / SOXF Transcription Factors Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Anticancer Res Year: 2014 Document type: Article Affiliation country: Poland
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / SOXF Transcription Factors Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Anticancer Res Year: 2014 Document type: Article Affiliation country: Poland